Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov 2;13(11):2561-2574.
doi: 10.1080/21645515.2017.1364322. Epub 2017 Aug 31.

Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations

Margaret E Gatti-Mays  1 , Jason M Redman  1 , Julie M Collins  1 , Marijo Bilusic  2
Affiliations
Review

Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations

Margaret E Gatti-Mays et al. Hum Vaccin Immunother. .

Abstract

Therapeutic cancer vaccines have gained significant popularity in recent years as new approaches for specific oncologic indications emerge. Three therapeutic cancer vaccines are FDA approved and one is currently approved by the EMA as monotherapy with modest treatment effects. Combining therapeutic cancer vaccines with other treatment modalities like radiotherapy (RT), hormone therapy, immunotherapy, and/or chemotherapy have been investigated as a means to enhance immune response and treatment efficacy. There is growing preclinical and clinical data that combination of checkpoint inhibitors and vaccines can induce immunogenic intensification with favorable outcomes. Additionally, novel methods for identifying targetable neoantigens hold promise for personalized vaccine development. In this article, we review the rationale for various therapeutic combinations, clinical trial experiences, and future directions. We also highlight the most promising developments that could lead to approval of novel therapeutic cancer vaccines.

Keywords: cancer vaccine; combination immunotherapy; immune-related response criteria; immunogenic modulation; immunotherapy.

PubMed Disclaimer

References

    1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al.. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422. doi:10.1056/NEJMoa1001294. PMID:20818862 - DOI - PubMed
    1. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al.. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780-88. doi:10.1200/JCO.2014.58.3377. PMID:26014293 - DOI - PubMed
    1. Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964-70. doi:10.1016/S0022-5347(05)64273-5. PMID:12394686 - DOI - PubMed
    1. Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: Independent or interdependent processes? Curr Opin Immunol. 2007;19(2):203-208. doi:10.1016/j.coi.2007.02.001. PMID:17292599 - DOI - PubMed
    1. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, et al.. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400-404. doi:10.1038/nature10755. PMID:22318521 - DOI - PMC - PubMed

MeSH terms

Substances